他克莫司在膜性肾病患者应用中的药学监护  

Pharmaceutical care of tacrolimus in patients with membranous nephropathy

作　　者：朱旭[1] 庞露[1] 王宝华 于丹[1] 肇丽梅[1] ZHU Xu;PANG Lu;WANG Bao-hua;YU Dan;ZHAO Li-mei(Department of Pharmacy,Shengjing Hospital of China Medical University,Shenyang 110004,Liaoning Province,China)

机构地区：[1]中国医科大学附属盛京医院药学部,辽宁沈阳110004

出　　处：《中国临床药理学杂志》2020年第15期2323-2324,2330,共3页The Chinese Journal of Clinical Pharmacology

基　　金：辽宁省教育厅科学研究课题资助项目(LK201611)。

摘　　要：他克莫司是治疗膜性肾病的常用免疫抑制药之一。临床药师依托循证药学分析药物相互作用对他克莫司血药浓度的影响,参与膜性肾病患者药物治疗方案的调整与优化。通过评估及平衡用药疗效与风险,为患者提供个体化的药学服务,促进慢性肾病患者合理、有效、安全用药。Tacrolimus is one of the immunosuppressive drugs that commonly used for the treatment of membranous nephropathy.According to evidence-based medicine,the pharmacists analyzed the influences of drug interactions on tacrolimus blood concentrations,and participated in adjustment and optimization of treatment in patients with membranous nephropathy.By evaluating and balancing the efficacy and risks of medication,individual pharmaceutical care can be provided for patients.It can help to promote rational,effective and safe medication for patients with chronic kidney disease.

关 键 词：膜性肾病 药学服务 相互作用 他克莫司 

分 类 号：R979.5[医药卫生—药品]